Table 2 The association of clinicopathological characteristics with results of CD8 (N=54)

Age years

Mean (SD)

50.1 (10.1)

51.6 (7.9)

t=−0.541, p=0.591 ^a

Tumor stage (N=39)

T1/2

5 (50)

5 (50)

p= 0.253

T3/4

21 (72.4)

8 (27.6)

L.N stage (N=28)

No

11 (73.3)

4 (26.7)

p=1 ^b

Yes

9 (69.2)

4 (30.8)

M stage (N=36)

No

21 (67.7)

10 (32.3)

p= 1^b

Yes

3 (60)

2 (40)

FIGO stage(N=38)

1/2

5 (62.5)

3 (37.5)

p= 1^b

3/4

20 (66.7)

10 (33.3)

Ascites (N=43)

No

11 (64.7)

6 (35.3)

p= 1

Yes

16 (61.5)

10 (38.5)

Residual tumor (N=39)

No

12 (54.5)

10 (45.5)

X²=1.04, p=0.343

Yes

12 (70.6)

5 (29.4)

Metastasis (N=39)

No

13 (76.5)

4 (23.5)

X²=1.3, p=0.318

Yes

13 (59.1)

9 (40.9)

Recurrence (N=38)

No

11 (64.7)

6 (35.3)

X²= 0.01, p=0.899

Yes

14 (66.7)

7 (33.3)

Peritoneal deposits (N= 45)

No

5 (55.6)

4 (44.4)

p= 0.711^b

Yes

23 (63.9)

13 (36.1)

Neoadjuvant therapy (N=35)

No

18 (81.8)

10 (76.9)

p=1^b

Yes

4 (18.2)

3 (23.1)

Ki-67 (N=53)

Low

14 (66.7)

7 (33.3)

X²=0.287, p=0.592

High

19 (59.4)

13 (40.6)

PDL1

Negative

7 (33.3)

14 (66.7)

X²=12.9, p≤0.001

Positive

27 (81.8)

6 (18.2)

CEA (N=15)

Median (min-max)

2.1 (0.1–64)

8 (2–48)

Z=−1.22, p=0.219^c

CA 125 (N=28)

Median (min-max)

212 (104–1268)

238 (169–1233)

Z= −0.712, p= 0.476^c